SCLXW:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.3

Change

-0.03 (-9.09)%

Market Cap

N/A

Volume

1.48K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+0.10 (+0.15%)

USD 202.13B
AMGN Amgen Inc

+2.60 (+0.87%)

USD 172.98B
SNY Sanofi ADR

-0.63 (-1.26%)

USD 134.67B
GILD Gilead Sciences Inc

-1.72 (-1.82%)

USD 111.44B
BIIB Biogen Inc

-2.49 (-1.48%)

USD 25.32B
GRFS Grifols SA ADR

-0.01 (-0.11%)

USD 6.92B
AMRN Amarin Corporation PLC

+0.02 (+3.11%)

USD 0.23B
MIRA MIRA Pharmaceuticals, Inc. Com..

-0.04 (-2.50%)

USD 0.03B
SCLX Scilex Holding Company

-0.03 (-3.80%)

N/A

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.67% 50% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.67% 50% F 33% F
Trailing 12 Months  
Capital Gain -37.49% 30% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.49% 30% F 20% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -22.83% 20% F 11% F
Dividend Return -22.83% 20% F 11% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 46.13% 20% F 41% F
Risk Adjusted Return -49.48% 30% F 14% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector